HIV Research Faces Setbacks as Funding Cuts Continue

The HIV epidemic remains a significant global health challenge, with millions still living with the virus. However, progress in combating HIV has been hampered by recent funding cuts impacting research and aid programs, a topic highlighted at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026.

Trump Administration Cuts Impact HIV Vaccine Development

Over the past year, the Trump administration implemented budget cuts that specifically affected global HIV aid and research. These cuts led to pauses and halts in research grants, and the indefinite suspension of HIV vaccine research due to funding reductions. In 2025, the administration terminated funding for several key HIV vaccine research programs.

Termination of CHAVD Funding

The Trump administration terminated $258 million in funding to the Center for HIV/AIDS Vaccine Development (CHAVD), including $129 million allocated to Duke University. Duke Chronicle reported on this decision in May 2025.

Broader Cuts to HIV Vaccine Research

Beyond CHAVD, the administration moved to end funding for a broad range of HIV vaccine research efforts, stating that current approaches were sufficient. CBS News detailed these cuts in February 2026, noting that researchers at the Duke Human Vaccine Institute and the Scripps Research Institute were affected. Clinical trials through the NIH’s HIV Vaccine Trials Network, involving Moderna, were as well position on pause.

A senior NIH official indicated that HHS instructed the agency to limit new funding for HIV vaccine research in the next fiscal year, with few exceptions. A budgetary rule change inflated the accounting for upfront costs of HIV vaccine studies, making it more difficult to secure funding.

Concerns from Researchers

Scientists expressed dismay at the cuts, fearing significant setbacks in the development of an effective HIV vaccine. Dennis Burton, an immunologist at the Scripps Research Institute, described the termination of a seven-year, $258 million NIH-funded program as “devastating,” noting the extensive effort invested in the research. NPR reported on these concerns in June 2025.

Experts warned that the cuts could result in a decade-long setback for HIV vaccine research. Forbes highlighted these warnings in June 2025.

Moving Forward

Despite these challenges, the HIV epidemic remains a top health priority. Experts emphasize the need for continued research and innovation to combat the virus and ultimately end the epidemic. The 4 I’s framework, as discussed at CROI 2026, may guide future efforts.